279 related articles for article (PubMed ID: 20848504)
1. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
Arijs I; Quintens R; Van Lommel L; Van Steen K; De Hertogh G; Lemaire K; Schraenen A; Perrier C; Van Assche G; Vermeire S; Geboes K; Schuit F; Rutgeerts P
Inflamm Bowel Dis; 2010 Dec; 16(12):2090-8. PubMed ID: 20848504
[TBL] [Abstract][Full Text] [Related]
2. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy.
Toedter G; Li K; Sague S; Ma K; Marano C; Macoritto M; Park J; Deehan R; Matthews A; Wu GD; Lewis JD; Arijs I; Rutgeerts P; Baribaud F
Inflamm Bowel Dis; 2012 Aug; 18(8):1399-410. PubMed ID: 22223479
[TBL] [Abstract][Full Text] [Related]
3. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles of ileal inflammatory bowel disease correlate with disease phenotype and advance understanding of its immunopathogenesis.
Ben-Shachar S; Yanai H; Baram L; Elad H; Meirovithz E; Ofer A; Brazowski E; Tulchinsky H; Pasmanik-Chor M; Dotan I
Inflamm Bowel Dis; 2013 Nov; 19(12):2509-21. PubMed ID: 24108111
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
[TBL] [Abstract][Full Text] [Related]
6. Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile.
Medrano LM; Taxonera C; González-Artacho C; Pascual V; Gómez-García M; Barreiro-de Acosta M; Pérez-Calle JL; Bermejo F; López-Sanromán A; Martín Arranz D; Gisbert JP; Mendoza JL; Martín J; Núñez C; Urcelay E
Mediators Inflamm; 2015; 2015():318207. PubMed ID: 26339133
[TBL] [Abstract][Full Text] [Related]
7. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
[TBL] [Abstract][Full Text] [Related]
8. Endoscopic monitoring of infliximab therapy in Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila PE; Sipponen T; Färkkilä MA
Inflamm Bowel Dis; 2011 Apr; 17(4):947-53. PubMed ID: 20860048
[TBL] [Abstract][Full Text] [Related]
9. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.
Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Inflamm Bowel Dis; 2009 Sep; 15(9):1295-301. PubMed ID: 19340881
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
Li Z; Arijs I; De Hertogh G; Vermeire S; Noman M; Bullens D; Coorevits L; Sagaert X; Schuit F; Rutgeerts P; Ceuppens JL; Van Assche G
Inflamm Bowel Dis; 2010 Aug; 16(8):1299-310. PubMed ID: 20196149
[TBL] [Abstract][Full Text] [Related]
11. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
12. Association of TRAP1 with infliximab-induced mucosal healing in Crohn's disease.
Park SH; Hong M; Lee HS; Ye BD; Hwang SW; Jung S; Baek J; Moon JW; Kim BM; Oh SH; Kim KM; Lee I; Im CN; Liu J; McGovern DPB; Yang SK; Song K
J Gastroenterol Hepatol; 2019 Dec; 34(12):2118-2125. PubMed ID: 31039275
[TBL] [Abstract][Full Text] [Related]
13. Selective downregulation of retinoic acid-inducible gene I within the intestinal epithelial compartment in Crohn's disease.
Funke B; Lasitschka F; Roth W; Penzel R; Meuer S; Saile M; Gretz N; Sido B; Schirmacher P; Autschbach F
Inflamm Bowel Dis; 2011 Sep; 17(9):1943-54. PubMed ID: 21830273
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Molnár T
Expert Opin Biol Ther; 2015; 15(9):1257-62. PubMed ID: 26134250
[TBL] [Abstract][Full Text] [Related]
15. Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.
Verstockt B; Verstockt S; Creyns B; Tops S; Van Assche G; Gils A; Ceuppens JL; Vermeire S; Ferrante M; Breynaert C
Aliment Pharmacol Ther; 2019 Mar; 49(5):572-581. PubMed ID: 30663072
[TBL] [Abstract][Full Text] [Related]
16. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
Arijs I; Li K; Toedter G; Quintens R; Van Lommel L; Van Steen K; Leemans P; De Hertogh G; Lemaire K; Ferrante M; Schnitzler F; Thorrez L; Ma K; Song XY; Marano C; Van Assche G; Vermeire S; Geboes K; Schuit F; Baribaud F; Rutgeerts P
Gut; 2009 Dec; 58(12):1612-9. PubMed ID: 19700435
[TBL] [Abstract][Full Text] [Related]
17. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy.
Schmidt C; Giese T; Hermann E; Zeuzem S; Meuer SC; Stallmach A
Inflamm Bowel Dis; 2007 Jan; 13(1):65-70. PubMed ID: 17206641
[TBL] [Abstract][Full Text] [Related]
19. Molecular patterns in human ulcerative colitis and correlation with response to infliximab.
Halloran B; Chang J; Shih DQ; McGovern D; Famulski K; Evaschesen C; Fedorak RN; Thiesen A; Targan S; Halloran PF
Inflamm Bowel Dis; 2014 Dec; 20(12):2353-63. PubMed ID: 25397893
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.
Liu C; Xia X; Wu W; Wu R; Tang M; Chen T; Xu F; Cong Y; Xu X; Liu Z
Clin Exp Immunol; 2013 Jul; 173(1):102-11. PubMed ID: 23607532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
